http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 08 Jul 2026 07:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Press+Releases/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html <p>MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bE8tpWepvNssLC2UwV-0o6afZTjh1y5GXeRBeLZ-CuwAgJYRT4k2esN3DvI_7TtH7Hs_I3o1iWj3s1zyDDWh00wVAyU8dlYsDjPpvw_Jfb4=" rel="nofollow" target="_blank">Pasithea Therapeutics Corp.</a> (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced management will participate in the Mind, Muscle &amp; Vision Summit, hosted by B. Riley Securities, on July 16, 2026, at the InterContinental Boston in Boston, Massachusetts.</p> <p>The Mind, Muscle &amp; Vision Summit will bring together leading biotechnology and pharmaceutical companies focused on neuropsychiatry, ophthalmology, neuroimmunology, neurodegeneration, and neuromuscular diseases. http://www.streetinsider.com/Globe+Newswire/Pasithea+Therapeutics+Announces+Participation+in+B.+Riley+Securities+Mind%2C+Muscle+%26amp%3B+Vision+Summit/26744147.html Wed, 08 Jul 2026 07:02:00 -0400 A.50202486 KTTA KTTAW O.47854289 O.53171475 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289 http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html <p>Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the appointment of Kartik Krishnan, M.D., Ph.D. as chief medical officer, effective May 1, 2026. The clinical-stage biotechnology company said Krishnan will oversee clinical development and medical strategy for PAS-004, its macrocyclic MEK inhibitor being developed for neurofibromatosis type 1.</p> <p>Krishnan brings over 20 years of experience in clinical development, regulatory affairs and research strategy. He previously served as chief executive officer at OncoNano Medicines and chief medical officer at Arcus Biosciences. Earlier in his career, he held clinical development roles at Genentech, BioMarin, Amgen and other pharmaceutical companies.</p> <p>During his tenure at Genentech, Krishnan contributed http://www.streetinsider.com/Management+Changes/Pasithea+names+Kartik+Krishnan+as+chief+medical+officer/26420807.html Mon, 04 May 2026 07:01:17 -0400 A.04794336 A.08435063 A.25838468 A.39245293 A.40151759 A.50100323 A.50112551 A.60001765 KTTA KTTAW O.00050368 O.00160376 O.00726495 O.01962945 O.10557543 O.12396261 O.20032280 O.20738543 O.47854289